Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The clinical trial used a combo of Verzenio and Femara in patients with recurrent endometrial cancer that’s estrogen receptor positive.
The oral targeted therapy Verzenio reduced relapse risk in extended follow-up from a recent study.
The oral targeted therapy lowered the risk of relapse in a late-stage study.
A study in mice suggests that therapies approved for breast cancer may also combat other types, including colorectal and stomach cancer.
The FDA is warning that these drugs used to treat advanced breast cancers may cause rare but severe inflammation of the lungs.
Precision medicine matches patients with the treatments most likely to work for them.
New treatment options are available for those with breast cancer that has metastasized.
Indication extended to include first-line treatment of HR-positive/HER2-negative advanced or metastatic disease.
Abemaciclib approved for first-line treatment of HR-positive, HER2-negative breast cancer that has spread.
Verzenio delayed disease progression among women with HR-positive/HER2-negative breast cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.